Medical news
-
WFH supports MASAC’s recommendation on the risks of gene therapy trials for hemophilia
On December 6, 2018, MASAC—the NHF’s Medical and Scientific Advisory Council—published recommendation #254, entitled, “MASAC Document Regarding Risks of Gene Therapy Trials for Hemophilia”. MASAC’s recommendation...
-
WFH Medical Advisory Board (MAB) supports MASAC’s recommendation on the use and management of emicizumab-kxwh (Hemlibra®) for hemophilia A with and without inhibitors
On December 6, 2018, MASAC—the NHF’s Medical and Scientific Advisory Council—published recommendation #255 entitled, “Recommendation on the Use and Management of Emicizumab-kxwh (Hemlibra®) for Hemophilia...
-
Now available: report on the Annual Global Survey 2017
The Report on the World Federation of Hemophilia (WFH) Annual Global Survey (AGS) 2017 is now available in print and online at www.wfh.org/globalsurvey. The report includes...
-
New gene therapy CME activity: Updates on Clinical Trials of Gene Therapy in Hemophilia
The World Federation of Hemophilia (WFH) is pleased to announce the launch of the fifth and final activity in Clinical Advances in Gene Therapy for...
-
WBDR reaches important milestones
The World Bleeding Disorders Registry (WBDR) provides a global platform for hemophilia treatment centres (HTCs) to collect standardized data on people with hemophilia. The WFH...
